Vasiliki (Vicky) Valla
Strategic Planning for MedTech, Pharma, Biotech
Regulatory Compliance | Regulatory Affairs | Regulatory Intelligence
Seasoned RA executive with a go-to-market mindset. Core focus on healthcare innovation and delivering regulatory and clinical value. Driving regulatory and clinical evidence strategies for MedTech & Pharma. Documented track record of projects around the world; primarily European and US Affairs.
Blessed with inspiring teachers and mentors, I have an instinct for sharing knowledge, liaising with people, prioritizing patient safety and improving care delivery. I will blend in or stand out according to the project's needs. Open-minded team player that won't stop until the job is done!
Reach out for full resume and samples of work.
-----------------------------------
My life mottos:
“Where shall I begin, please your Majesty?" he asked.
"Begin at the beginning," the King said gravely, "and go on till you come to the end: then stop.”
― Lewis Carroll, Alice's Adventures in Wonderland & Through the Looking-Glass
“We pass through this world but once. Few tragedies can be more extensive than the stunting of life, few injustices deeper than the denial of an opportunity to strive or even to hope, by a limit imposed from without, but falsely identified as lying within.”
― Stephen Jay Gould, The Mismeasure of Man
Phone: +306944504062
Regulatory Compliance | Regulatory Affairs | Regulatory Intelligence
Seasoned RA executive with a go-to-market mindset. Core focus on healthcare innovation and delivering regulatory and clinical value. Driving regulatory and clinical evidence strategies for MedTech & Pharma. Documented track record of projects around the world; primarily European and US Affairs.
Blessed with inspiring teachers and mentors, I have an instinct for sharing knowledge, liaising with people, prioritizing patient safety and improving care delivery. I will blend in or stand out according to the project's needs. Open-minded team player that won't stop until the job is done!
Reach out for full resume and samples of work.
-----------------------------------
My life mottos:
“Where shall I begin, please your Majesty?" he asked.
"Begin at the beginning," the King said gravely, "and go on till you come to the end: then stop.”
― Lewis Carroll, Alice's Adventures in Wonderland & Through the Looking-Glass
“We pass through this world but once. Few tragedies can be more extensive than the stunting of life, few injustices deeper than the denial of an opportunity to strive or even to hope, by a limit imposed from without, but falsely identified as lying within.”
― Stephen Jay Gould, The Mismeasure of Man
Phone: +306944504062
less
InterestsView All (13)
Uploads
Papers by Vasiliki (Vicky) Valla
Specification: 14 pages plus covers, in English, supplied by email as a PDF.
This article has been published in the November 2021 issue of the Journal of Medical Device Regulation.
platinum-based complexes of 4-hydroxy-androst-4-ene-3,17-dione (Formestane,
4-OHA), which is clinically administered to treat breast cancer.
Material and Methods: The organotin compounds were synthesized by reacting the
corresponding triorganotin hydroxide with 4-OHA and the Pt complex by reacting the
sodium salt of 4-OHA with K2PtCl4. The new compounds structure was studied by
H-NMR, ESI-MS and MALDI-MS. Cytotoxicity (CI%) was evaluated by colorimetric
SRB assay. Cell lines K-562, MCF-7, HT-29, HeLaS3 and MRC-5 were used. Aromatase
inhibition was evaluated after Matsui2005, who proposed a competitive ELISA assay
for the determination of P450arom inhibition.
Results: The spectroscopic analysis provides evidence on the formation of a chelate
ring, with the Sn in a five-coordinated environment exhibiting distorted trigonal
bipyramidal geometry. 4-OH-A is coordinated to the Pt in a bidentating fashion,
forming a 5-membered chelate. The amine and chloride ligands complete the square
planar coordination environment. Fragmentation is based on the formation of the
[SnR3] cation and the 4-OHA anion. A similar pattern was found for the Pt complex.
Major fragments involve the formation of adducts with solvent and/or water molecules
and oligomers.
Regarding the cytotoxicity profile, the trimethyltin derivative was the most toxic.
K562 and MRC-5 cell lines were resistant to the triphenyltin compound, while HeLaS3
and MCF-7 were more sensitive.
Interestingly, the triphenyltin and Pt complex bear similar cytotoxicities, implying
that it is the intermediate fragments which determine this effect and not the central
metal ([Me3Sn]+ is more toxic than [Ph3Sn]+ and [Pt(NH3)Cl]+). On the other hand,
the formation of [M-H2O] and [M+H2O]) fragments, which are involved in
substitution reactions, indicates that cytotoxicity mechanism maybe similar to that of
cis-platin.
The compounds are moderate aromatase inhibitors exhibiting IC50 values 9,6lM
[(Ph3Sn)-4-OHA]; 11,12 lM [(Me3Sn)-4-OHA] and 8,2 lM [Pt-(4-OHA)-NH3Cl]
respectively. The AI50 value determined herein expresses the ability of aromatase
receptors to recognize the steroidal part of the new compounds. The metal-androstanic
ring distance affects the inhibitory effect.
Conclusions: The ongoing research, including spectroscopic and enzyme kinetic
studies, will reveal more data on the aromatase inhibition mode and the antiproliferation induced by